Repository logo
 
Publication

Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach

2021-05-29Journal article Restricted access
Simple item page
dc.contributor.authorGomes, Andreia 
dc.contributor.authorCoelho, Pedro
dc.contributor.authorSoares, Raquel 
dc.contributor.authorCosta, Raquel 
dc.date.accessioned2021-11-24T16:42:36Z
dc.date.available2021-11-24T16:42:36Z
dc.date.issued2021-05-29
dc.description.abstractThe umbilical cord has been proved to be an easy-access, reliable, and useful source of mesenchymal stem cells (MSC) for clinical applications due to its primitive, immunomodulatory, non-immunogenic, secretory and paracrine, migratory, proliferative, and multipotent properties. This set of characteristics has recently attracted great research interest in the fields of nanotechnology and regenerative medicine and cellular therapy. Accumulating evidence supports a pronounced therapeutic potential of MSC in many different pathologies, from hematology to immunology, wound-healing, tissue regeneration, and oncology. Diabetes mellitus, branded the epidemic of the century, is considered a chronic metabolic disorder, representing a major burden for health system sustainability and an important public health challenge to modern societies. The available treatments for type 2 diabetes mellitus (T2DM) still rely mainly on combinations of oral antidiabetic agents with lifestyle and nutritional adjustments. Despite the continuous development of novel and better hypoglycemic drugs, their efficacy is limited in the installment and progression of silent T2DM complications. T2DM comorbidities and mortality rates still make it a serious, common, costly, and long-term manageable disease. Recently, experimental models, preclinical observations, and clinical studies have provided some insights and preliminary promising results using umbilical cord MSCs to treat and manage diabetes. This review focuses on the latest research and applications of human-derived umbilical cord MSC in the treatment and management of T2DM, exploring and systematizing the key effects of both umbilical cord MSC and its factor-rich secretome accordingly with the major complications associated to T2DM.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationGomes, A., Coelho, P., Soares, R., & Costa, R. (2021). Human umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approach. Cell and Tissue Research, 385(3), 497-518. https://doi.org/10.1007/s00441-021-03461-4pt_PT
dc.identifier.doi10.1007/s00441-021-03461-4pt_PT
dc.identifier.eissn1432-0878
dc.identifier.urihttp://hdl.handle.net/10400.22/18946
dc.language.isoengpt_PT
dc.publisherSpringerpt_PT
dc.relation.publisherversionhttps://link.springer.com/article/10.1007/s00441-021-03461-4pt_PT
dc.subjectType 2 diabetes mellituspt_PT
dc.subjectUmbilical cord mesenchymal cellspt_PT
dc.subjectCell therapypt_PT
dc.subjectVascular complicationspt_PT
dc.subjectClinical applicationpt_PT
dc.subjectRegenerative medicinept_PT
dc.titleHuman umbilical cord mesenchymal stem cells in type 2 diabetes mellitus: the emerging therapeutic approachpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage518pt_PT
oaire.citation.startPage497pt_PT
oaire.citation.titleCell and Tissue Researchpt_PT
oaire.citation.volume385pt_PT
person.familyNameCoelho
person.givenNamePedro
person.identifier.ciencia-idBE18-3DB2-8D79
person.identifier.orcid0000-0002-2343-1108
person.identifier.ridAAZ-9239-2020
person.identifier.scopus-author-id57214054449
rcaap.rightsclosedAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationeb030614-4140-437b-8ac3-f59c52566ecf
relation.isAuthorOfPublication.latestForDiscoveryeb030614-4140-437b-8ac3-f59c52566ecf

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_Pedro Coelho 1.pdf
Size:
1.57 MB
Format:
Adobe Portable Document Format
Download

Collections

ESS - CQB - Artigos